Cargando…
Resolution of a neurotrophic keratopathy associated hypopyon with cenegermin
PURPOSE: We present a novel case of a neurotrophic keratopathy associated inflammatory hypopyon that resolved after initiation of therapy with cenegermin (Oxervate; Dompe, Milan, Italy), a recombinant human nerve growth factor (rhNGF). This finding illustrates the potential of cenegermin in advanced...
Autores principales: | Zambino, Nick, Syed, Zeba A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296075/ https://www.ncbi.nlm.nih.gov/pubmed/34307960 http://dx.doi.org/10.1016/j.ajoc.2021.101113 |
Ejemplares similares
-
Neurotrophic keratopathy: Clinical presentation and effects of cenegermin
por: Bu, Julia Bing, et al.
Publicado: (2022) -
Observational study of cenegermin for the treatment of limbal stem
cell deficiency associated with neurotrophic keratopathy
por: Arboleda, Alejandro, et al.
Publicado: (2022) -
Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy
por: Pedrotti, Emilio, et al.
Publicado: (2022) -
Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up
por: García-Delpech, Salvador, et al.
Publicado: (2022) -
A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops
por: Fausto, Riccardo, et al.
Publicado: (2020)